Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 2/20 | 0.30 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.30 |
| ▸ | CPN1 | P15169 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338296 | 0.82 | NCF1 (0.45) | NCF1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL12423890 | 0.77 | NCF1 (0.48) | NCF1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL23539665 | 0.76 | CPN1 (0.38) | HRH3ANPEPENPEPCPN1CPB2 | |
| SCHEMBL1504772 | 0.75 | NCF1 (0.46) | NCF1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL10843765 | 0.74 | KDM4E (0.37) | LMNAKDM4EANPEPENPEP | |
| SCHEMBL8972336 | 0.73 | NCF1 (0.46) | NCF1GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL19090016 | 0.72 | NCF1 (0.48) | NCF1GNAI3GNAO1GNAI1HRH4 | |
| SCHEMBL21941844 | 0.72 | NCF1 (0.32) | NCF1 | |
| SCHEMBL102076 | 0.72 | NCF1 (0.52) | NCF1GNAI3GNAO1GNAI1HRH4 | |
| SCHEMBL2671538 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | NCF1 1626/4885CACNA2D1 1994/4885CACNA1B 970/4885 |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | NCF1 1781/4885CACNA2D1 2032/4885CACNA1B 973/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | NCF1 2299/4885CACNA2D1 3193/4885CACNA1B 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.